registry, as of 2026-07-08Stale
https://clinicaltrials.gov/study/NCT05616013
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese. Overall status COMPLETED. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 507. Conditions Obesity; Obese; Overweight or Obesity. A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48 Placebo/30 mg/kg Bimagrumab 40.0 Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48 10/30 mg/kg Bimagrumab 58.1 Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48 30 mg/kg Bimagrumab 83.8 Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48 Placebo + 1.0 mg Semaglutide 73.3 Percentage of Participants With Redu
ClinicalTrials.gov NCT05616013 protocol and results modules
registry, as of 2026-03-27Stale
https://clinicaltrials.gov/study/NCT05933499
Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity. Overall status RECRUITING. Phases PHASE2. Lead sponsor Massachusetts General Hospital. Enrollment 63. Conditions Obesity. In adults with obesity seeking treatment, weight loss would ideally be composed almost exclusively of fat mass. However, loss of muscle mass and bone are unintentional consequences of weight loss, which may have negative effects on health by lessening improvements in glucose and
ClinicalTrials.gov NCT05933499 protocol and results modules
registry, as of 2025-09-24Stale
https://clinicaltrials.gov/study/NCT06901349
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes. Overall status WITHDRAWN. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 0. Conditions Obesity; Overweight. The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.
ClinicalTrials.gov NCT06901349 protocol and results modules
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05616013
preserve/increase muscle mass in the presence of weight and/or fat mass loss. Bimagrumab Human monoclonal antibody to the activin receptor type II Semaglutide Glucagon-like peptide-1 (GLP-1) receptor agonist Placebo Placebo
NCT05616013 description or intervention text
Registry NCT05616013
Phase Phase 2
Status Completed
Enrollment 507
Start 2022-11-16
Primary completion 2024-05-16
Study completion 2025-06-14
Placebo/30 mg/kg Bimagrumab
Dose 30 mg
Regimen weekly
Weeks 4
Population Obesity; Obese; Overweight or Obesity
participants with at least 5 percent body weight loss, 40 %, week 48Stale
deaths
participants with diarrhoea, 10 participantsStale
participants with nausea, 9 participantsStale
participants with vomiting, 1 participantsStale
10/30 mg/kg Bimagrumab
Dose 30 mg
Regimen weekly
Weeks 4
Comparator placebo
Population Obesity; Obese; Overweight or Obesity
participants with at least 5 percent body weight loss, 58.1 %, week 48Stale
deaths
participants with diarrhoea, 27 participantsStale
participants with nausea, 15 participantsStale
participants with vomiting, 5 participantsStale
30 mg/kg Bimagrumab
Dose 30 mg
Regimen weekly
Weeks 4
Comparator placebo
Population Obesity; Obese; Overweight or Obesity
participants with at least 5 percent body weight loss, 97.7 %, week 48Stale
deaths
participants with diarrhoea, 25 participantsStale
participants with nausea, 20 participantsStale
participants with vomiting, 7 participantsStale
Placebo + 1.0 mg Semaglutide
Dose 1.0 mg
Regimen weekly
Weeks 4
Population Obesity; Obese; Overweight or Obesity
participants with at least 5 percent body weight loss, 73.3 %, week 48Stale
deaths
participants with diarrhoea, 19 participantsStale
participants with nausea, 25 participantsStale
participants with vomiting, 6 participantsStale
Placebo + 2.4 mg Semaglutide
Dose 2.4 mg
Regimen weekly
Weeks 4
Population Obesity; Obese; Overweight or Obesity
participants with at least 5 percent body weight loss, 92.2 %, week 48Stale
deaths
participants with diarrhoea, 21 participantsStale
participants with nausea, 26 participantsStale
participants with vomiting, 10 participantsStale
10 mg/kg Bimagrumab + 1.0 mg Semaglutide
Dose 1.0 mg
Regimen weekly
Weeks 4
Comparator placebo
Population Obesity; Obese; Overweight or Obesity
participants with at least 5 percent body weight loss, 97.6 %, week 48Stale
deaths
participants with diarrhoea, 27 participantsStale
participants with nausea, 23 participantsStale
participants with vomiting, 6 participantsStale
10 mg/kg Bimagrumab + 2.4 mg Semaglutide
Dose 2.4 mg
Regimen weekly
Weeks 4
Comparator placebo
Population Obesity; Obese; Overweight or Obesity
participants with at least 5 percent body weight loss, 100 %, week 48Stale
deaths
participants with diarrhoea, 29 participantsStale
participants with nausea, 34 participantsStale
participants with vomiting, 10 participantsStale
30 mg/kg Bimagrumab + 1.0 mg Semaglutide
Dose 1.0 mg
Regimen weekly
Weeks 4
Comparator placebo
Population Obesity; Obese; Overweight or Obesity
30 mg/kg Bimagrumab + 2.4 mg Semaglutide
Dose 2.4 mg
Regimen weekly
Weeks 4
Comparator placebo
Population Obesity; Obese; Overweight or Obesity
Registry NCT06901349
Phase Phase 2
Status Withdrawn
Enrollment 0
Start 2025-05-23
Primary completion 2025-06-10
Study completion 2025-06-10
Catalyst Primary completion. 2025-06-10. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale
Bimagrumab Dose 1 + Tirzepatide Placebo
Population Obesity; Overweight
Bimagrumab Dose 2 + Tirzepatide Placebo
Population Obesity; Overweight
Tirzepatide Dose 1 + Bimagrumab Placebo
Population Obesity; Overweight
Tirzepatide Dose 2 + Bimagrumab Placebo
Population Obesity; Overweight
Bimagrumab Dose 2 + Tirzepatide Dose 1
Comparator placebo
Population Obesity; Overweight
Bimagrumab Dose 1 + Tirzepatide Dose 1
Comparator placebo
Population Obesity; Overweight
Bimagrumab Dose 2 + Tirzepatide Dose 2
Comparator placebo
Population Obesity; Overweight
Bimagrumab Dose 1 + Tirzepatide Dose 2
Comparator placebo
Population Obesity; Overweight
Bimagrumab Placebo + Tirzepatide Placebo
Population Obesity; Overweight